Entropy Technologies LP Invests $901,000 in Option Care Health, Inc. (NASDAQ:OPCH)

Entropy Technologies LP purchased a new position in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 38,817 shares of the company's stock, valued at approximately $901,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Westfield Capital Management Co. LP grew its stake in Option Care Health by 10.2% in the third quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company's stock worth $203,204,000 after purchasing an additional 599,589 shares in the last quarter. Global Alpha Capital Management Ltd. boosted its position in shares of Option Care Health by 108.3% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 49,818 shares of the company's stock worth $1,559,000 after purchasing an additional 25,905 shares in the last quarter. Graypoint LLC purchased a new position in Option Care Health in the 4th quarter worth $1,161,000. Victory Capital Management Inc. raised its stake in Option Care Health by 4,432.8% in the 3rd quarter. Victory Capital Management Inc. now owns 1,621,593 shares of the company's stock worth $50,756,000 after acquiring an additional 1,585,818 shares during the last quarter. Finally, Barclays PLC raised its stake in Option Care Health by 180.1% in the 3rd quarter. Barclays PLC now owns 310,194 shares of the company's stock worth $9,708,000 after acquiring an additional 199,454 shares during the last quarter. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on OPCH. Jefferies Financial Group upgraded Option Care Health from a "hold" rating to a "buy" rating and lifted their price objective for the company from $26.00 to $35.00 in a research note on Thursday, January 23rd. The Goldman Sachs Group cut Option Care Health from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $38.00 to $27.00 in a report on Monday, November 4th. Bank of America upgraded Option Care Health from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $26.00 to $33.00 in a report on Monday, January 13th. JPMorgan Chase & Co. boosted their target price on Option Care Health from $38.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, Barrington Research boosted their target price on Option Care Health from $32.00 to $33.00 and gave the stock an "outperform" rating in a report on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Option Care Health has a consensus rating of "Moderate Buy" and a consensus price target of $32.25.

Option Care Health Trading Down 1.1 %

NASDAQ OPCH traded down $0.34 on Friday, reaching $31.46. The stock had a trading volume of 1,115,120 shares, compared to its average volume of 1,760,941. The firm has a market capitalization of $5.35 billion, a price-to-earnings ratio of 26.44, a P/E/G ratio of 2.19 and a beta of 1.35. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. Option Care Health, Inc. has a 12-month low of $21.39 and a 12-month high of $34.63. The stock has a fifty day moving average price of $26.69 and a two-hundred day moving average price of $27.93.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.